anti-Lethal Factor
Product code
IQ-NLF
Clone
IQNLF
Isotype
Human IgG1
Specificity
IQNLF reacts with domain I of the Lethal Factor component of the Lethal Toxin of Bacillus anthracis1. Domain I of Lethal Factor contains the binding region for Protective Antigen.
Antigen distribution
IQNLF reacts with B. anthracis’ Lethal Factor in saline solutions, culture media and peripheral blood. Binding of IQNLF to Lethal Factor interferes with the formation of Lethal Toxin, and, as such, IQNLF has Lethal Toxin-neutralizing capacity2 (EC50, 0.1 nM). IQNLF has demonstrated to be protective against Bacillus anthracis infection in animals, in pre- and post-exposure settings, especially when given in combination with IQNPA.
Applications
IQNLF can be applied in ELISAs and toxin neutralization assays. Since Lethal Factor has been shown to be present in blood early after B. anthracis infection3, anti-Lethal Factor antibodies could also be used for the detection of Lethal Factor in blood for rapid diagnostic and treatment monitoring purposes4.
Usage
The reagents is formulated for use in ELISA and toxin neutralization assay. Since applications vary, each investigator should titrate the reagent to obtain optimal results. For research use only. Patent owned by Hero Biotechnology BV (www.herobiotech.com).
References
1. Albrecht, M.T. et al. 2007. Infect. Immunol. 75. 5425-5433
2. Whiting, G. et al. 2012. Toxins 4. 28-41
3. Boyer, A.E. et al. 2009. Infect. Immunol. 77. 3432-3441
4. Gallegos-Candela, M. 2018. Anal. Biochem. 543. 97-107
anti-Protective Antigen
Product code
IQ-NPA
Clone
IQNPA
Isotype
Human IgG1
Specificity
IQNPA reacts with domain IV of the Protective Antigen component of the Lethal Toxin and the Edema Toxin of Bacillus anthracis1. Domain IV of Protective Antigen contains the Protective Antigen host cell binding site.
Antigen distribution
IQNPA reacts with B. anthracis’ Protective Antigen in saline solutions, culture media and peripheral blood. Binding of IQNPA to Protective Antigen interferes with the binding of Protective Antigen to the targeted host cell and with the formation of B. anthracis’ Lethal Toxin and Edema Toxin. As such, IQNPA has Lethal Toxin-neutralizing capacity2 (EC50, 0.3 nM). IQNPA has demonstrated to be highly protective against Bacillus anthracis infection in animals, in pre- and post-exposure settings, especially when given in combination with IQNLF.
Applications
IQNPA can be applied in ELISAs and toxin neutralization assays. Anti-Protective Antigen antibodies can also be used to detect B. anthracis spores using flow cytometry3.
Usage
The reagents is formulated for use in ELISA and toxin neutralization assay. Since applications vary, each investigator should titrate the reagent to obtain optimal results. For research use only. Patent owned by Hero Biotechnology BV (www.herobiotech.com).
References
1. Albrecht, M.T. et al. 2007. Infect. Immunol. 75. 5425-5433
2. Whiting, G. et al. 2012. Toxins 4. 28-41
3. Schumacher, W.C. et al. 2008. Appl. Env. Microbiol. 74. 5220-5223